Recruiting

Observational Study

Sponsor:

University Health Network, Toronto

Code:

NCT02760238

Conditions

Primary Myelofibrosis

Polycythemia Vera

Essential Thrombocythemia

Mastocytosis

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Observational

Study Details

Brief summary:

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Conditions

Primary Myelofibrosis

Polycythemia Vera

Essential Thrombocythemia

Mastocytosis

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Study ID

NCT02760238

Start date

Apr, 2015

Status verified date

Aug, 2024

Completion date

Oct 31, 2027

Anticipated

Primary completion date

Oct 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Diagnosis of one of the following myeloproliferative neoplasms (MPNs):

  • Atypical CML (aCML)
  • Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
  • Chronic myelomonocytic leukemia (CMML)
  • Chronic neutrophilic leukemia (CNL),
  • Essential thrombocythemia (ET),
  • Juvenile myelomonocytic leukemia (JMML),
  • Mastocytosis, MPN unclassifiable
  • MPN/MDS unclassifiable,
  • Primary myelofibrosis (PMF),
  • Post-essential thrombocythemia myelofibrosis (post-ET MF),
  • Post-polycythemia vera MF (post-PV MF)
  • Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)

Exclusion Criteria:

  • None

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients with a diagnosis of MPN

Patients with a myeloproliferative neoplasm (MPN) diagnosis:

Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T

Interventions

Observational

Primary outcome measure

  • Survival [ Time Frame: Annually or at the time of transformation of disease, up to 10 years ]

Central Contacts and Locations

Central contacts

Vikas Gupta, MD

416-946-4521vikas.gupta@uhn.ca

Jaime O. Claudio, PhD

416-946-4501jclaudio@uhnresearch.ca

Locations

Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G 1Z5

Contacts

Vikas Gupta, MD

416-946-2885vikas.gupta@uhn.ca

More Information

Sponsor

University Health Network, Toronto

Last update posted

Aug 27, 2024

Last verified

Aug, 2024

Keywords

  • myeloproliferative neoplasm
  • myelodysplastic syndrome
  • registry
  • leukemia
  • Bone Marrow Diseases
  • Hematologic Diseases
  • Neoplasms

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2024-08-27.